Michael Aboud

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 347 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop et al. · Clinical Infectious Diseases · 2020 · 273 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 212 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno et al. · AIDS · 2021 · 201 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17